Table 3.
Other outcomes
| COVID-19 cohort (n = 309) | Pre-COVID-19 cohort (n = 407) | p value | |
|---|---|---|---|
| Reperfusion therapy | |||
| IV thrombolysis, n (%) | 50/180 (28) | 59/194 (30) | 0.58 |
| Endovascular thrombectomy, n (%) | 20/180 (11) | 23/194 (12) | 0.82 |
| Successful reperfusion after endovascular thrombectomy, n (%)a | 16/20 (80) | 15/22 (68) | 0.38 |
| Process measures | |||
| Door-to-needle time (median, minutes, IQR)b | 31 (21–51) | 28 (21–40) | 0.39 |
| First door-to-groin time (median, minutes, IQR)c | 112 (70–155) | 96 (61–128) | 0.24 |
| Door comprehensive stroke center to groin time (median, minutes, IQR)d | 60 (48–78) | 61 (48–75) | 0.88 |
| Complications | |||
| ICU admission, n (%) | 16/309 (5) | 20/407 (5) | 0.87 |
| sICH, n (%) | 0/309 | 2/407 (1) | 0.38 |
| Mortality within 7 days, n (%) | 17/201 (9) | 19/382 (5) | 0.10 |
| Discharge destination | 0.44 | ||
| Home, n (%) | 157/283 (55) | 225/397 (56) | |
| Nursing home, n (%) | 9/283 (3) | 14/397 (4) | |
| Rehabilitation center, n (%) | 37/283 (13) | 37/397 (9) | |
| Other hospital, n (%) | 64/283 (22) | 104/397 (26) | |
| In-hospital death, n (%) | 16/283 (6) | 17/397 (4) |
Data on reperfusion therapy and process measures only regard patients with ischemic strokes
IV indicates intravenous; IQR interquartile range; COVID-19 coronavirus disease 2019; ICU intensive-care unit; sICH symptomatic intracranial hemorrhage
aDefined as extended thrombolysis in cerebral infarction score of 2b–3. Missing values, n (%):b7(6), cfor transfer patients, the first-door-to-groin time is calculated as the time interval between presentation at the primary stroke center and groin puncture at the comprehensive stroke center, missing values, n (%) 4(9) d0(0), e29 (4)